Mobile

A double-blind, randomised, placebo-controlled, parallel-group, multicentre, phase II study to assess the efficacy of AZD7009 (AR-H065522XX) given intravenously (infusion for 15 or 30 minutes) to pati...

Update Il y a 4 ans
Reference: EUCTR2005-000204-13

A double-blind, randomised, placebo-controlled, parallel-group, multicentre, phase II study to assess the efficacy of AZD7009 (AR-H065522XX) given intravenously (infusion for 15 or 30 minutes) to patients for conversion of atrial fibrillation

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To study the efficacy of iv AZD7009 in all treatment groups versus placebo, in conversion of AF. The primary outcome variable for the evaluation of this objective is: -the proportion of patients that have converted from AF within 90 min from start of infusion. Conversion has occurred if SR (and/or AV junctional rhythm) is maintained for at least 2 min A secondary outcome variable evaluating the primary objective is: -the time to conversion from AF from start of infusion up to 90 min

Inclusion criteria

  • Atrial fibrillation (AF)

Links